Archives of Medical Science最新文献

{"title":"Insulin-like growth factor-1 reduces cardiac autosis through decreasing AMPK/FOXO1 signaling and Na⁺/K⁺-ATPase-Beclin-1 interaction.","authors":"Katarina Banjac, Milan Obradovic, Sonja Zafirovic, Esma R Isenovic","doi":"10.5114/aoms/177618","DOIUrl":"https://doi.org/10.5114/aoms/177618","url":null,"abstract":"<p><strong>Introduction: </strong>Insulin-like growth factor-1 (IGF-1) promotes survival and inhibits cardiac autophagy disruption.</p><p><strong>Methods: </strong>Male Wistar rats were treated with IGF-1 (50 µg/kg), and 24 h after injection hearts were excised. The level of interaction between Beclin-1 and the α₁ subunit of sodium/potassium-adenosine triphosphates (Na⁺/K⁺-ATPase), and phosphorylated forms of IGF-1 receptor/insulin receptor (IGF-1R/IR), forkhead box protein O1 (FOXO1) and AMP-activated protein kinase (AMPK) were measured.</p><p><strong>Results: </strong>The results indicate that IGF-1 decreased Beclin-1's association with Na⁺/K⁺-ATPase (<i>p</i> < 0.05), increased IGF-1R/IR and FOXO1 phosphorylation (<i>p</i> < 0.05), and decreased AMPK phosphorylation (<i>p</i> < 0.01) in rats' hearts.</p><p><strong>Conclusions: </strong>The new IGF-1 therapy may control autosis and minimize cardiomyocyte mortality.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 3","pages":"1011-1015"},"PeriodicalIF":3.0,"publicationDate":"2024-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11264057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141756820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of ornidazole for pericoronitis: a meta-analysis and systematic review.","authors":"Ruobing Du, Kai Ba, Yaxin Yang, Yueyue Zhao, Yupeng Lin","doi":"10.5114/aoms/171907","DOIUrl":"10.5114/aoms/171907","url":null,"abstract":"<p><strong>Introduction: </strong>Timely and effective treatments of pericoronitis are very important. We aimed to evaluate the role of ornidazole in the treatment of pericoronitis, to provide insights for clinical pericoronitis treatment.</p><p><strong>Material and methods: </strong>The PubMed, Clinical trials, EMBASE, Science Direct, Cochrane Library, China National Knowledge Infrastructure (CNKI), Weipu and Wanfang databases were searched to find randomized controlled trials (RCTs) of ornidazole in the treatment of pericoronitis from the establishment of the database to March 15, 2023. Review Manager 5.3 software was used for meta-analysis.</p><p><strong>Results: </strong>A total of 16 RCTs involving 2004 patients were included. The results of the meta-analysis showed that the effective rate of ornidazole treatment was significantly higher than that of the routine treatment group (RR = 1.22, 95% CI (1.15, 1.29), <i>p</i> < 0.001). Ornidazole treatment was beneficial to reduce the oral bacterial density (MD = -26.13, 95% CI (-32.08, -21.51)), time to pain disappearance (MD = -0.64, 95% CI (-0.92, -0.17)) and time to disappearance of redness and swelling of the teeth crown (MD = -1.45, 95% CI (-2.43, -1.01)) compared to the routine treatment (all <i>p</i> = 0.05). No publication bias was found by the funnel plots and Egger test (<i>p</i> = 0.206).</p><p><strong>Conclusions: </strong>Ornidazole is effective in the treatment of pericoronitis, with more advantages. Still, the effects and safety of ornidazole in the treatment of pericoronitis need to be evaluated by more high-quality RCTs with larger sample sizes.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 1","pages":"189-195"},"PeriodicalIF":3.8,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10895945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139982225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Position Paper of the Polish Expert Group on the Use of Pitavastatin in the Treatment of Lipid Disorders in Poland Endorsed by the Polish Lipid Association.","authors":"Maciej Banach, Stanisław Surma, A. Kapłon-Cieślicka, Przemysław Mitkowski, Grzegorz Dzida, Tomasz Tomasik, A. Mastalerz-Migas","doi":"10.5114/aoms/175879","DOIUrl":"https://doi.org/10.5114/aoms/175879","url":null,"abstract":"LDL-C is the basic lipid parameter that should be measured to determine CV risk and determines the aim and LLT target. LLT improves cardiovascular prognosis and prolongs life in both primary and secondary cardiovascular prevention. Despite the availability of effective lipid-lowering drugs and solid data on their beneficial effects, the level of LDL-C control is highly insufficient. This is related to physician inertia and patients' fear of side effects. The development of lipidology has made drugs available with a good safety profile and enabling personalisation of therapy. Pitavastatin, the third most potent statin, is characterised by a lower risk of muscle complications and NOD due to its being metabolised differently. Thus, pitavastatin is a good therapeutic option in patients at high risk of diabetes or with existing diabetes, and in patients at cardiovascular risk. This Position Paper indicates the place of using pitavastatin in the treatment of lipid disorders.","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"62 1","pages":""},"PeriodicalIF":3.8,"publicationDate":"2023-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139236002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel scoring system for early diagnosis of necrotizing enterocolitis: integrating clinical and laboratory data with urinary caveolin-1 levels.","authors":"Brigitta I R V Corebima, Rinawati Rohsiswatmo, Dewi Santosaningsih, Wisnu Barlianto, Kusworini Handono","doi":"10.5114/aoms/173390","DOIUrl":"https://doi.org/10.5114/aoms/173390","url":null,"abstract":"<p><strong>Introduction: </strong>Necrotizing enterocolitis (NEC) poses a significant threat to preterm infants, with nonspecific early manifestations complicating timely diagnosis. Therefore, this study aimed to develop a novel scoring system for early diagnosis of NEC, incorporating clinical and laboratory data with urinary caveolin-1 levels.</p><p><strong>Material and methods: </strong>A single-center prospective cohort study was conducted at a tertiary hospital in East Java, Indonesia. NEC diagnosis was established by Bell's criteria and proven gut dysbiosis. Urinary levels of claudin-2, caveolin-1, and epidermal growth factor (EGF) were assessed as potential indicators of tight junction disruption. The selected urine biomarker cutoff value was determined using symbolic classification analysis and combined with clinical and laboratory parameters from Bell's criteria to create an NEC scoring system, validated with the Aiken index. Sensitivity and specificity analyses were performed.</p><p><strong>Results: </strong>Thirty-four neonates, comprising NEC, preterm non-NEC, and term infants, were included. qPCR analysis highlighted elevated <i>Klebsiella</i>, <i>Lactobacillus</i>, <i>Clostridium</i>, and <i>Bacteroides</i> levels in NEC patients, indicating a gut dysbiosis trend. Among 3 biomarkers, caveolin-1 ≥ 17.81 ng/dl on day 3 demonstrated 72.86% negative predictive value and 87.50% positive predictive value. The combined scoring system which comprised abdominal cellulitis, distension, radiology, advanced resuscitation at birth, prematurity or low birthweight, platelet count, sepsis, orogastric retention, metabolic acidosis and caveolin-1 findings exhibited an AUC of 0.922 (95% CI: 0.81-1.00, <i>p</i> < 0.001), with ≥ 1.81 as the cutoff, offering 93% sensitivity and 94% specificity.</p><p><strong>Conclusions: </strong>Urine caveolin-1 on day 3 signifies enterocyte tight junction damage and the acute phase of NEC in premature infants. The proposed scoring system demonstrates good performance in predicting NEC incidence in preterm infants.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 2","pages":"444-456"},"PeriodicalIF":3.8,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11094821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anemia in elderly rheumatoid arthritis patients: a cohort study.","authors":"Zhanjuan Sun, Haiyan Shao, Huijie Liu, Linxiao Ma","doi":"10.5114/aoms/172443","DOIUrl":"https://doi.org/10.5114/aoms/172443","url":null,"abstract":"<p><strong>Introduction: </strong>Anemia is common in elderly patients with rheumatoid arthritis (RA). This study aimed to evaluate the current status and influencing factors of anemia in RA patients, to provide insights for clinical RA treatment and care.</p><p><strong>Material and methods: </strong>This study included elderly patients with high RA activity treated in our hospital from June 1, 2021 to December 31, 2022 for analysis. The characteristics of RA patients were analyzed. Pearson correlation and logistic regression analysis were conducted to analyze the influencing factors of anemia in elderly patients with RA.</p><p><strong>Results: </strong>A total of 285 RA patients were included. The incidence of anemia in high RA activity patients was 62.46%. There were significant differences in the course of RA, hemoglobin (Hb), low-density lipoprotein cholesterol (LDL-C), platelet/lymphocyte rate (PLR) and albumin (Alb) between RA patients with anemia and without anemia (all <i>p</i> < 0.05). Pearson correlation analysis indicated that course of RA (<i>r</i> = 0.522), Hb (<i>r</i> = 0.797), LDL-C (<i>r</i> = 0.558), PLR (<i>r</i> = 0.615) and Alb (<i>r</i> = 0.604) were correlated with anemia in patients with high RA activity (all <i>p</i> < 0.05). Logistic regression analysis indicated that course of RA ≥ 8 years (OR = 2.584, 95% CI: 1.822-3.647), LDL-C ≤ 2.8 mmol/l (OR = 3.202, 95% CI: 2.804-3.431), PLR ≥ 8 (OR = 2.183, 95% CI: 1.744-2.457), Alb ≤ 35 g/l (OR = 1.716, 95% CI: 1.401-2.006) were the risk factors of anemia in elderly patients with high RA activity (all <i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>Anemia in elderly patients with high RA activity is closely related to the course of RA, LDL-C, PLR and Alb. Close attention should be paid to the monitoring of those indicators to take early intervention measures to improve the prognosis of RA patients.</p>","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"20 2","pages":"457-463"},"PeriodicalIF":3.8,"publicationDate":"2023-11-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11094838/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140961453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The year in nutrition medicine 2023","authors":"Arrigo F.G. Cicero, Federica Fogacci","doi":"10.5114/aoms/174787","DOIUrl":"https://doi.org/10.5114/aoms/174787","url":null,"abstract":"","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"56 10","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135545808","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment with progesterone attenuates proliferation of endometrial polyps (EP) via regulation of expression of miR-320b and its target gene, MCL1","authors":"Yan Su, Weiwei Feng, Haofan Shi","doi":"10.5114/aoms/171308","DOIUrl":"https://doi.org/10.5114/aoms/171308","url":null,"abstract":"The mechanism underlying the pathogenesis of endometrial polyps (EP) remains unclear. Endocrinopathy can be corrected by counteracting the effect of oestrogenic stimulation with progesterone, and systemic administration of pregestational agents was shown to block the effect of estrogenic stimulation and reverse the process of excessive endometrial growth [1]. Progesterone is an essential factor involved in the development of endometrial receptivity, and it maintains the homeostasis of the female endocrine system by blocking the synthesis of gonadotropin in the hypothalamus [2]. Meanwhile, the expression of miR-320 is down-regulated in patients with breast cancer [3]. By increasing the expression of miR-320, progesterone may block the infiltration of cells from the trophectoderm and uterus. Progesterone has been shown to affect the expression of multiple","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"56 9","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135545809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of fecal Fusobacterium nucleatum in colorectal cancer","authors":"Chen Xing, Li Zhihao, Ji Di","doi":"10.5114/aoms/174261","DOIUrl":"https://doi.org/10.5114/aoms/174261","url":null,"abstract":"","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"58 8","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135544587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global burden of neck pain in 204 countries from 1990–2019","authors":"Yongfu Li, Shunan Zhang, Peng Shu","doi":"10.5114/aoms/170962","DOIUrl":"https://doi.org/10.5114/aoms/170962","url":null,"abstract":"Introduction The estimation of global burden of neck pain is lacking. To estimate the trends and burden of neck pain by sex, age, region, and sociodemographic index (SDI). Material and methods The incidence and disability-adjusted life years (DALY) data for neck pain were extracted from the Global Burden of Disease 2019 database. The estimated annual percent change (EAPC) and 95% confidence intervals (CIs) were used to assess the trends in age-standardized incidence and DALY rates from 1990 to 2019. Results From 1990 to 2019, the global age-standardized incidence rate and age-standardized DALY rate indicated downward trends, with EAPCs of –0.06 and –0.09, respectively. The EAPCs of the age-standardized incidence rate and age-standardized DALY rate were negatively correlated with the SDI in 2019, respectively. The age-standardized incidence rates and age-standardized DALY rates in regions with a high SDI indicated a downward trend, including in high-income North America, Australia, and New Zealand. In 2019, the Philippines and high-income North America had the highest age-standardized incidence and age-standardized DALY rates. From 1990 to 2019, the areas which increased most rapidly in the age-standardized incidence rate and age-standardized DALY rate were in tropical Latin America (EAPCs of 0.53 and 0.60, respectively). Brazil had the most rapid increase in the age-standardized incidence rate and age-standardized DALY rate (EAPCs of 0.55 and 0.61, respectively). Conclusions The age-standardized incidence rate and age-standardized DALY rate of neck pain decreased globally from 1990 to 2019. However, there were significant differences concerning sex, age, and regional distributions. Therefore, targeted prevention interventions and risk factor control measures should be reasonably allocated.","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"49 12","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135723678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2023: The year in cardiovascular disease - the year of new and prospective lipid lowering therapies. Can we render dyslipidemia a rare disease by 2024?","authors":"Maciej Banach, Stanisław Surma, Peter P Toth","doi":"10.5114/aoms/174743","DOIUrl":"https://doi.org/10.5114/aoms/174743","url":null,"abstract":"In 2023 there are still even 75% of patients over the LDL-C target, and hypercholesterolemia is the most common and the worst monitored CVD risk factor. How it is possible, considering the knowledge we have on the role of cholesterol in the process of atherosclerosis, ASCVD and its complications, on the methods of lipid disorders diagnosis, prevention, and treatment. Nowadays, almost 4 million deaths per year are attributed to LDL-C, and even 2/3 of all CVD deaths to ASCVD, therefore hypothetically we should easily prevent few to several million of deaths with early diagnosis, and early and intensive non-pharmacological and pharmacological therapies. Moreover, lipidology is the area with the highest number of new and ongoing trials with new medications that have already appeared and will soon be available. Therefore, we have no doubt that year 2023 should be called the year of new and prospective LLTs.","PeriodicalId":8278,"journal":{"name":"Archives of Medical Science","volume":"22 10","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135875170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}